Urology
Volume 73, Issue 4 , Pages 697-705 , April 2009

Combined Androgen Blockade Revisited: Emerging Options for the Treatment of Castration-Resistant Prostate Cancer

  • Matthew N. Simmons
    • ,
  • Eric A. Klein

      Affiliations

    • Corresponding Author InformationReprint requests: Eric Klein, M.D., Cleveland Clinic Lerner College of Medicine, Section of Urologic Oncology, Glickman Urological and Kidney Institute 100, 9500 Euclid Avenue, Cleveland OH 44195

Received 28 July 2008 ,Accepted 16 September 2008.

References 

  1. Huggins C. Endocrine control of prostatic cancer. Science. 1943;97:541–544
  2. Gittes RF. Carcinoma of the prostate. N Engl J Med. 1991;324:236–245
  3. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45
  4. Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology. 2001;57:727–732
  5. Labrie F, Dupont A, Belanger A, et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med. 1982;5:267–275
  6. Shally AV, Arimura A, Baba Y, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochim Biophys Res Comm. 1971;43:393–399
  7. Peets EA, Henson MF, Neri R. On the mechanism of the anti-androgenic action of flutamide (alpha-alpha-alpha-trifluoro-2-methyl-4'-nitro-m-propionotoluidide) in the rat. Endocrinology. 1974;94:532–540
  8. Seguin C, Cusan L, Belanger A, et al. Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat. Mol Cell Endocrinol. 1981;21:37–41
  9. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419–424
  10. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–1042
  11. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491–1498
  12. Lukka H, Waldron T, Klotz L, et al. Maximal androgen blockade for the treatment of metastatic prostate cancer-a systematic review. Curr Oncol. 2006;13:81–93
  13. Zhou ZX, Lane MV, Kemppainen JA, et al. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol. 1995;9:208–218
  14. Gregory CW, Johnson RT, Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001;61:2892–2898
  15. Compagno D, Merle C, Morin A, et al. SIRNA-directed in Vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS ONE. 2007;2:e1006
  16. Hara T, Miyazaki H, Lee A, et al. Androgen receptor and invasion in prostate cancer. Cancer Res. 2008;68:1128–1135
  17. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66:2815–2825
  18. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447–4454
  19. Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006;91:3850–3856
  20. Reddy GP, Barrack ER, Dou QP, et al. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem. 2006;98:1408–1423
  21. D'Antonio J. AR (androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease)). Atlas Genet Cytogenet Oncol Haematol. 2008;http://AtlasGeneticsOncology.org/Genes/ARID685chXq612.htmlJanuary. Accessed on July 1, 2008
  22. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332:1393–1398
  23. Bohl CE, Gao W, Miller DD, et al. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A. 2005;102:6201–6206
  24. Wirth MP, Froschermaier SE. The antiandrogen withdrawal syndrome. Urol Res. 1997;25(Suppl 2):S67–S71
  25. Hirawat S, Budman DR, Kreis W. The androgen receptor: structure, mutations, and antiandrogens. Cancer Invest. 2003;21:400–417
  26. Brooke GN, Parker MG, Bevan CL. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene. 2007;27:2941–2950
  27. Klokk TI, Kurys P, Elbi C, et al. Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol Cell Biol. 2007;27:1823–1843
  28. Ettinger SL, Sobel R, Whitmore TG, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 2004;64:2212–2221
  29. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54:5474–5478
  30. Zhang F, Lee J, Lu S, et al. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res. 2005;11:4512–4520
  31. Chen ML, Xu PZ, Peng XD, et al. The deficiency of Akt1 is sufficient to suppress tumor development in PTEN± mice. Genes Dev. 2006;20:1569–1574
  32. Kaarbo M, Klokk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays. 2007;29:1227–1238
  33. Singh AP, Bafna S, Chaudhary K, et al. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett. 2008;259:28–38
  34. Heinrich E, Schally AV, Buchholz S, et al. Dose-dependent growth inhibition in Vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. [e-pub ahead of print] Prostate. 2008;68:1763–1772
  35. Van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol. 2008;54:805–815
  36. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025–1033
  37. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–4571
  38. Hsieh AC, Ryan CJ. Novel concepts in androgen receptor blockade. Cancer J. 2008;14:11–14
  39. Hwang DJ, Yang J, Xu H, et al. Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorg Med Chem. 2006;14:6525–6538
  40. Kelly WK. New drugs in the management of advanced prostate cancer. Cancer J. 2008;14:10
  41. Nickols NG, Dervan PB. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci U S A. 2007;104:10418–10423
  42. Mu Z, Hachem P, Hensley H, et al. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo. Prostate. 2008;68:599–609
  43. Hadaschik BA, Gleave ME. Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol. 2007;25:413–419
  44. Fizazi K, Le Maitre A, Hudes G, et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007;8:994–1000
  45. Sonpavde G, Aparicio A, Guttierez I, et al. Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. Clin Genitourin Cancer. 2007;5:457–459
  46. Dasmahapatra GP, Didolkar P, Alley MC, et al. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res. 2004;10:5242–5252
  47. Chee KG, Longmate J, Quinn DI, et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007;5:433–437
  48. Kaseb AO, Chinnakannu K, Chen D, et al. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 2007;67:7782–7788
  49. Marrocco DL, Tilley WD, Bianco-Miotto T, et al. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 2007;6:51–60
  50. Maruyama-Takahashi K, Shimada N, Imada T, et al. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows antitumour activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions. Prostate. 2008;68:640–650
  51. Ryan CJ, Harzstark AH, Rosenberg J, et al. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int. 2008;101:436–439
  52. Warren R, Liu G. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs. 2008;17:1237–1245
  53. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res. 2007;13:764s–769s

PII: S0090-4295(08)01662-2

doi: 10.1016/j.urology.2008.09.040

Urology
Volume 73, Issue 4 , Pages 697-705 , April 2009

Article Tools

* Image Usage & Resolution